Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine

JACC: Basic to Translational Science

Volumn 2, Issue 3, 2017, Pages 311-327

  Johnson, Kipp W ^a,b   Shameer, Khader ^a,b   Glicksberg, Benjamin S ^a,b   Readhead, Ben ^a,b   Sengupta, Partho P ^b   Björkegren, Johan L M ^b,c   Kovacic, Jason C ^b   Dudley, Joel T ^a,b  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

cardiology; clinical informatics; multi omics; precision medicine; translational bioinformatics

Indexed keywords

EID: 85033597806     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.11.010     Document Type: Review

References (159)

1. Iqbal, J., Gunn, J., Serruys, P.W., Coronary stents: historical development, current status and future directions. Br Med Bull 106 (2013), 193–211.
2. Cushman, D.W., Ondetti, M.A., History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17 (1991), 589–592.
3. Fox, K.A., Steg, P.G., Eagle, K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA 297 (2007), 1892–1900.
4. Ho, P.M., Magid, D.J., Shetterly, S.M., et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155 (2008), 772–779.
5. Sidney, S., Quesenberry, C.P. Jr., Jaffe, M.G., et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol 1 (2016), 594–599.
6. Smith, J.G., Newton-Cheh, C., Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol 83 (2015), 131–141.
7. Kessler, T., Vilne, B., Schunkert, H., The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med 8 (2016), 688–701.
8. Pjanic, M., Miller, C.L., Wirka, R., Kim, J.B., DiRenzo, D.M., Quertermous, T., Genetics and genomics of coronary artery disease. Curr Cardiol Rep, 18, 2016, 102.
9. Allen, N.B., Lloyd-Jones, D., Hwang, S.J., et al. Genetic loci associated with ideal cardiovascular health: a meta-analysis of genome-wide association studies. Am Heart J 175 (2016), 112–120.
10. Visscher, P.M., Brown, M.A., McCarthy, M.I., Yang, J., Five years of GWAS discovery. Am J Hum Genet 90 (2012), 7–24.
11. Bjorkegren, J.L., Kovacic, J.C., Dudley, J.T., Schadt, E.E., Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Coll Cardiol 65 (2015), 830–845.
12. Shameer, K., Denny, J.C., Ding, K., et al. A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum Genet 133 (2014), 95–109.
13. Horrobin, D.F., Realism in drug discovery—could Cassandra be right?. Nat Biotechnol 19 (2001), 1099–1100.
14. Pammolli, F., Magazzini, L., Riccaboni, M., The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10 (2011), 428–438.
15. Fordyce, C.B., Roe, M.T., Ahmad, T., et al. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol 65 (2015), 1567–1582.
16. Joy, T.R., Hegele, R.A., The failure of torcetrapib: what have we learned?. Br J Pharmacol 154 (2008), 1379–1381.
17. McLain, J.H., Alsterda, A.J., Arora, R.R., Cholesteryl ester transfer protein inhibitors: trials and tribulations. J Cardiovasc Pharmacol Ther, 2016 Aug 10 [E-pub ahead of print].
18. Barter, P.J., Rye, K.A., Cholesteryl ester transfer protein inhibition is not yet dead—pro. Arterioscler Thromb Vasc Biol 36 (2016), 439–441.
19. Chen, B., Butte, A.J., Network medicine in disease analysis and therapeutics. Clin Pharmacol Ther 94 (2013), 627–629.
20. Hodos, R.A., Kidd, B.A., Shameer, K., Readhead, B.P., Dudley, J.T., In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8 (2016), 186–210.
21. Antman, E.M., Loscalzo, J., Precision medicine in cardiology. Nat Rev Cardiol 13 (2016), 591–602.
22. Shah, S.H., Arnett, D., Houser, S.R., et al. Opportunities for the cardiovascular community in the precision medicine initiative. Circulation 133 (2016), 226–231.
23. Jaffe, S., Planning for US Precision Medicine Initiative underway. Lancet 385 (2015), 2448–2449.
24. Ashley, E.A., The precision medicine initiative: a new national effort. JAMA 313 (2015), 2119–2120.
25. Collins, F.S., Varmus, H., A new initiative on precision medicine. N Engl J Med 372 (2015), 793–795.
26. Wang, H.M., Liao, C.T., Yen, T.C., et al. Clues toward precision medicine in oral squamous cell carcinoma: utility of next-generation sequencing for the prognostic stratification of high- risk patients harboring neck lymph node extracapsular extension. Oncotarget 7 (2016), 63082–63092.
27. Hirsch, F.R., Scagliotti, G.V., Mulshine, J.L., et al. Lung cancer: current therapies and new targeted treatments. Lancet 389 (2017), 299–311.
28. Kerr, K.M., Lopez-Rios, F., Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?. Ann Oncol 27:Suppl 3 (2016), iii16–iii24.
29. Stella, G.M., Gentile, A., Baderacchi, A., Meloni, F., Milan, M., Benvenuti, S., Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med, 14, 2016, 256.
30. Ruderfer, D.M., Charney, A.W., Readhead, B., et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry 3 (2016), 350–357.
31. Ashley, E.A., Butte, A.J., Wheeler, M.T., et al. Clinical assessment incorporating a personal genome. Lancet 375 (2010), 1525–1535.
32. Kullo, I.J., Jouni, H., Austin, E.E., et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES Clinical Trial). Circulation 133 (2016), 1181–1188.
33. Shameer, K., Klee, E.W., Dalenberg, A.K., Kullo, I.J., Whole exome sequencing implicates an INO80D mutation in a syndrome of aortic hypoplasia, premature atherosclerosis, and arterial stiffness. Circ Cardiovasc Genet 7 (2014), 607–614.
34. Feero, W.G., Guttmacher, A.E., Collins, F.S., Genomic medicine—an updated primer. N Engl J Med 362 (2010), 2001–2011.
35. Guttmacher, A.E., Collins, F.S., Genomic medicine—a primer. N Engl J Med 347 (2002), 1512–1520.
36. Miotto, R., Li, L., Kidd, B.A., Dudley, J.T., Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. Sci Rep, 6, 2016 May 17, 26094, 10.1038/srep26094.
37. Adami, C., Ofria, C., Collier, T.C., Evolution of biological complexity. Proceedings of the National Academy of Sciences 97 (2000), 4463–4468.
38. Goldstein, B.A., Navar, A.M., Carter, R.E., Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. Eur Heart J, 2016 Jul 19 [E-pub ahead of print].
39. Mandl, K.D., Kohane, I.S., Escaping the EHR trap—the future of health IT. N Engl J Med 366 (2012), 2240–2242.
40. Bolton, R.J., Hand, D.J., Unsupervised profiling methods for fraud detection. Proc Credit Scoring and Credit Control VII, 2001, 5–7.
41. Sengupta, P.P., Huang, Y.M., Bansal, M., et al. Cognitive machine-learning algorithm for cardiac imaging: a pilot study for differentiating constrictive pericarditis from restrictive cardiomyopathy. Circ Cardiovasc Imaging, 9, 2016, e004330.
42. Narula, S., Shameer, K., Salem Omar, A.M., Dudley, J.T., Sengupta, P.P., Machine-learning algorithms to automate morphological and functional assessments in 2D echocardiography. J Am Coll Cardiol 68 (2016), 2287–2295.
43. Shameer, K., Pugalenthi, G., Kandaswamy, K.K., Sowdhamini, R., 3dswap-pred: prediction of 3D domain swapping from protein sequence using Random Forest approach. Protein Pept Lett 18 (2011), 1010–1020.
44. Shameer, K., Pugalenthi, G., Kandaswamy, K.K., Suganthan, P.N., Archunan, G., Sowdhamini, R., Insights into protein sequence and structure-derived features mediating 3D domain swapping mechanism using support vector machine based approach. Bioinform Biol Insights 4 (2010), 33–42.
45. Ammad-Ud-Din, M., Khan, S.A., Malani, D., et al. Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics 32 (2016), i455–i463.
46. Vural, S., Wang, X., Guda, C., Classification of breast cancer patients using somatic mutation profiles and machine learning approaches. BMC Syst Biol, 10(Suppl 3), 2016, 62.
47. Stamile, C., Kocevar, G., Cotton, F., Maes, F., Sappey-Marinier, D., Huffel, S.V., Multi-parametric non-negative matrix factorization for longitudinal variations detection in white matter fiber-bundles. IEEE J Biomed Health Inform, 2016 Aug 3 [E-pub ahead of print].
48. Camara, P.G., Rosenbloom, D.I., Emmett, K.J., Levine, A.J., Rabadan, R., Topological data analysis generates high-resolution, genome-wide maps of human recombination. Cell Syst 3 (2016), 83–94.
49. Alagappan, M., Jiang, D., Denko, N., Koong, A.C., A multimodal data analysis approach for targeted drug discovery involving topological data analysis (TDA). Adv Exp Med Biol 899 (2016), 253–268.
50. Nielson, J.L., Paquette, J., Liu, A.W., et al. Topological data analysis for discovery in preclinical spinal cord injury and traumatic brain injury. Nat Commun, 6, 2015, 8581.
51. Hinks, T., Zhou, X., Staples, K., et al. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet, 385(Suppl 1), 2015, S42.
52. Tan, J., Ung, M., Cheng, C., Greene, C.S., Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders. Pac Symp Biocomput 20 (2015), 132–143.
53. Singh, R., Lanchantin, J., Robins, G., Qi, Y., DeepChrome: deep-learning for predicting gene expression from histone modifications. Bioinformatics 32 (2016), i639–i648.
54. Huynh, B.Q., Li, H., Giger, M.L., Digital mammographic tumor classification using transfer learning from deep convolutional neural networks. J Med Imaging (Bellingham), 3, 2016, 034501.
55. Janowczyk, A., Madabhushi, A., Deep learning for digital pathology image analysis: A comprehensive tutorial with selected use cases. J Pathol Inform, 7, 2016, 29.
56. Liang, Z., Huang, J.X., Zeng, X., Zhang, G., DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions. BMC Med Genomics, 9(Suppl 2), 2016, 48.
57. Choi, E., Schuetz, A., Stewart, W.F., Sun, J., Using recurrent neural network models for early detection of heart failure onset. J Am Med Inform Assoc 24 (2017), 361–370.
58. Ekins, S., The Next Era: Deep learning in pharmaceutical research. Pharm Res 33 (2016), 2594–2603.
59. Gawehn, E., Hiss, J.A., Schneider, G., Deep learning in drug discovery. Mol Inform 35 (2016), 3–14.
60. Ortiz, A., Munilla, J., Gorriz, J.M., Ramirez, J., Ensembles of deep learning architectures for the early diagnosis of the Alzheimer's disease. Int J Neural Syst, 26, 2016, 1650025.
61. Ngo, T.A., Lu, Z., Carneiro, G., Combining deep learning and level set for the automated segmentation of the left ventricle of the heart from cardiac cine magnetic resonance. Med Image Anal 35 (2016), 159–171.
62. Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., Zhavoronkov, A., Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm 13 (2016), 2524–2530.
63. Li, L., Cheng, W.Y., Glicksberg, B.S., et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med, 7, 2015, 311ra174.
64. Houle, D., Govindaraju, D.R., Omholt, S., Phenomics: the next challenge. Nat Rev Genet 11 (2010), 855–866.
65. Gottesman, O., Kuivaniemi, H., Tromp, G., et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med 15 (2013), 761–771.
66. National Human Genome Research Institute. Electronic Medical Records and Genomics (eMERGE) Network. Available at: https://www.genome.gov/27540473/electronic-medical-records-and-genomics-emerge-network/. Accessed April 23, 2017.
67. PheKB. What is the Phenotype KnowledgeBase? Available at: https://phekb.org. Accessed April 23, 2017.
68. Kirby, J.C., Speltz, P., Rasmussen, L.V., et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc 23 (2016), 1046–1052.
69. Oellrich, A., Collier, N., Groza, T., et al. The digital revolution in phenotyping. Brief Bioinform 17 (2016), 819–830.
70. Zemojtel, T., Kohler, S., Mackenroth, L., et al. Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome. Sci Transl Med, 6, 2014, 252ra123.
71. Drouin, A., Giguere, S., Deraspe, M., et al. Predictive computational phenotyping and biomarker discovery using reference-free genome comparisons. BMC Genomics, 17, 2016, 754.
72. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med, 372, 2015, 1677.
73. Bedi, O., Dhawan, V., Sharma, P.L., Kumar, P., Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol 389 (2016), 695–712.
74. Alfonsi, J.E., Hegele, R.A., Gryn, S.E., Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?. Curr Atheroscler Rep, 18, 2016, 24.
75. Birnbaum, Y., Ye, Y., Pleiotropic effects of statins: the role of eicosanoid production. Curr Atheroscler Rep 14 (2012), 135–139.
76. Antonopoulos, A.S., Margaritis, M., Shirodaria, C., Antoniades, C., Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 108 (2012), 840–848.
77. Mihos, C.G., Salas, M.J., Santana, O., The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18 (2010), 298–304.
78. Tashakkor, A.Y., Moghaddamjou, A., Chen, L., Cheung, W.Y., Predicting the risk of cardiovascular comorbidities in adult cancer survivors. Curr Oncol 20 (2013), e360–e370.
79. Crepaldi, G., Scire, C.A., Carrara, G., et al. Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS One, 11, 2016, e0146991.
80. Johnson, R.J., Feig, D.I., Nakagawa, T., Sanchez-Lozada, L.G., Rodriguez-Iturbe, B., Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 26 (2008), 381–391.
81. Surendran, P., Drenos, F., Young, R., et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet 48 (2016), 1151–1161.
82. Kent, S.T., Shimbo, D., Huang, L., et al. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007–2010. PLoS One, 9, 2014, e105888.
83. Ambrosius, W.T., Sink, K.M., Foy, C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 11 (2014), 532–546.
84. James, P.A., Oparil, S., Carter, B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
85. Francis, G.S., Cogswell, R., Thenappan, T., The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success?. J Am Coll Cardiol 64 (2014), 1775–1776.
86. Louridas, G.E., Lourida, K.G., Systems biology and clinical phenotypes of heart failure syndrome. J Am Coll Cardiol 65 (2015), 1269–1270.
87. Eckstein, D., Korabathina, R., Heart failure update: diagnosis and classification. FP Essent 442 (2016), 11–17.
88. Vaduganathan, M., Greene, S.J., Ambrosy, A.P., Gheorghiade, M., Butler, J., The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10 (2013), 85–97.
89. Gheorghiade, M., Larson, C.J., Shah, S.J., et al. Developing new treatments for heart failure: focus on the heart. Circ Heart Fail, 9, 2016.
90. Ahmad, T., Pencina, M.J., Schulte, P.J., et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol 64 (2014), 1765–1774.
91. Madias, J.E., Applying cluster analysis to data of previously published chronic heart failure trials. J Am Coll Cardiol 65 (2015), 1268–1269.
92. Ahmad, T., Felker, G.M., Reply: applying cluster analysis to data of previously published chronic heart failure trials: systems biology and clinical phenotypes of heart failure syndrome. J Am Coll Cardiol 65 (2015), 1270–1271.
93. Welch, T.D., Yang, E.H., Reeder, G.S., Gersh, B.J., Modern management of acute myocardial infarction. Curr Probl Cardiol 37 (2012), 237–310.
94. Talukdar, H.A., Foroughi Asl, H., Jain, R.K., et al. Cross-tissue regulatory gene networks in coronary artery disease. Cell Syst 2 (2016), 196–208.
95. Franzen, O., Ermel, R., Cohain, A., et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353 (2016), 827–830.
96. Rymer, J.A., Newby, L.K., Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era. Circulation 131 (2015), 1234–1235.
97. Shurlock, B., The emergence of cardiovascular imaging as a subspecialty and individualized treatment of coronary artery disease: two related trends. Eur Heart J 35 (2014), 3392–3393.
98. Gijsberts, C.M., den Ruijter, H.M., Asselbergs, F.W., Chan, M.Y., de Kleijn, D.P., Hoefer, I.E., Biomarkers of coronary artery disease differ between Asians and Caucasians in the general population. Glob Heart 10 (2015), 301–311.e11.
99. Kleber, M.E., Goliasch, G., Grammer, T.B., et al. Evolving biomarkers improve prediction of long-term mortality in patients with stable coronary artery disease: the BIO-VILCAD score. J Intern Med 276 (2014), 184–194.
100. Darabi, F., Aghaei, M., Movahedian, A., Pourmoghadas, A., Sarrafzadegan, N., The role of serum levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome. Mol Cell Biochem 422 (2016), 51–60.
101. Cheng, J., Chen, Y., Xu, B., Wu, J., He, F., Association of soluble fibrinogen-like protein 2 with the severity of coronary artery disease. Intern Med 55 (2016), 2343–2350.
102. Genoux, A., Lichtenstein, L., Ferrieres, J., et al. Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Med, 14, 2016, 125.
103. Stone, P.A., Thompson, S.N., Khan, M., Northfield, E., Schillinger, R., Skaff, P., The impact of biochemical markers on major adverse cardiovascular events and contralateral carotid artery stenosis progression following carotid interventions. Ann Vasc Surg 38 (2017), 144–150.
104. Li, H.Y., Zhao, X., Liu, Y.Z., et al. Plasma microRNA-126-5p is associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris. Cell Physiol Biochem 39 (2016), 837–846.
105. Barabasi, A.L., Oltvai, Z.N., Network biology: understanding the cell's functional organization. Nat Rev Genet 5 (2004), 101–113.
106. Giri, K., Shameer, K., Zimmermann, M.T., et al. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem 25 (2014), 1078–1090.
107. Burt, R.S., Kilduff, M., Tasselli, S., Social network analysis: foundations and frontiers on advantage. Annu Rev Psychol 64 (2013), 527–547.
108. Vidal, M., Cusick, M.E., Barabasi, A.L., Interactome networks and human disease. Cell 144 (2011), 986–998.
109. Glicksberg, B.S., Li, L., Cheng, W.Y., et al. An integrative pipeline for multi-modal discovery of disease relationships. Pac Symp Biocomput, 2015, 407–418.
110. Glicksberg, B.S., Li, L., Badgeley, M.A., et al. Comparative analyses of population-scale phenomic data in electronic medical records reveal race-specific disease networks. Bioinformatics 32 (2016), i101–i110.
111. Novac, N., Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 34 (2013), 267–272.
112. Sirota, M., Dudley, J.T., Kim, J., et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med, 3, 2011, 96ra77.
113. Shameer, K., Readhead, B., Dudley, J.T., Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. Curr Top Med Chem 15 (2015), 5–20.
114. RepurposeDB. Repositioning investigations. Available at: http://repurposedb.dudleylab.org/. Accessed April 23, 2017.
115. Packer, M., Bristow, M.R., Cohn, J.N., et al., for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996), 1349–1355.
116. Swedberg, K., Hjalmarson, A., Waagstein, F., Wallentin, I., Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1 (1979), 1374–1376.
117. Epstein, S.E., Braunwald, E., The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. Ann Intern Med 65 (1966), 20–27.
118. Sanchez, L.S., de la Monte, S.M., Filippov, G., Jones, R.C., Zapol, W.M., Bloch, K.D., Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43 (1998), 163–168.
119. Barnett, C.F., Machado, R.F., Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2 (2006), 411–422.
120. Ghofrani, H.A., Osterloh, I.H., Grimminger, F., Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5 (2006), 689–702.
121. Bertolini, F., Sukhatme, V.P., Bouche, G., Drug repurposing in oncology—patient and health systems opportunities. Nat Rev Clin Oncol 12 (2015), 732–742.
122. Deftereos, S., Giannopoulos, G., Papoutsidakis, N., et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 62 (2013), 1817–1825.
123. Brown, S.A., Sandhu, N., Herrmann, J., Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol 12 (2015), 718–731.
124. RepurposeDB. Drugs. Available at: http://repurposedb.dudleylab.org/browseDrugs. Accessed April 23, 2017.
125. Bharadwaj, U., Eckols, T.K., Kolosov, M., et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 34 (2015), 1341–1353.
126. Corbett, A., Pickett, J., Burns, A., et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 11 (2012), 833–846.
127. Rukov, J.L., Wilentzik, R., Jaffe, I., Vinther, J., Shomron, N., Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 15 (2014), 648–659.
128. Millan, M.J., Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110 (2006), 135–370.
129. Lu, J.J., Pan, W., Hu, Y.J., Wang, Y.T., Multi-target drugs: the trend of drug research and development. PLoS One, 7, 2012, e40262.
130. Zimmermann, G.R., Lehar, J., Keith, C.T., Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12 (2007), 34–42.
131. Medina-Franco, J.L., Giulianotti, M.A., Welmaker, G.S., Houghten, R.A., Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 18 (2013), 495–501.
132. Masters, P.A., O'Bryan, T.A., Zurlo, J., Miller, D.Q., Joshi, N., Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163 (2003), 402–410.
133. Allington, D.R., Rivey, M.P., Quinupristin/dalfopristin: a therapeutic review. Clin Ther 23 (2001), 24–44.
134. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4 (2008), 682–690.
135. Heidenreich, P.A., Trogdon, J.G., Khavjou, O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123 (2011), 933–944.
136. Kullo, I.J., Shameer, K., Jouni, H., et al. The ATXN2-SH2B3 locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study. Front Genet, 5, 2014, 166.
137. Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case- control study. Lancet 364 (2004), 937–952.
138. Pearson, T.A., Blair, S.N., Daniels, S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002), 388–391.
139. cBioPortal for Cancer Genomics. Available at: http://www.cbioportal.org/. Accessed April 23, 2017.
140. Cerami, E., Gao, J., Dogrusoz, U., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2 (2012), 401–404.
141. Tang, X., Baheti, S., Shameer, K., et al. The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. Nucleic Acids Res, 42, 2014, e172.
142. Aelion, C.M., Airhihenbuwa, C.O., Alemagno, S., et al. The US Cancer Moonshot initiative. Lancet Oncol 17 (2016), e178–e180.
143. Kennedy Sheldon, L., Oncology nurses and the Cancer Moonshot 2020. Clin J Oncol Nurs 20 (2016), 355–356.
144. American Heart Association News. ‘1 Team, 1 Vision’—AHA, Google Life Sciences launch $50 million project. Available at: http://news.heart.org/american-heart-association-google-life-sciences-seeking-novel-strategies-to-prevent-heart-disease/. Accessed April 23, 2017.
145. Pitt, G.S., Cardiovascular precision medicine: hope or hype?. Eur Heart J 36 (2015), 1842–1843.
146. Eden, C., Johnson, K.W., Gottesman, O., Bottinger, E.P., Abul-Husn, N.S., Medical student preparedness for an era of personalized medicine: findings from one US medical school. Per Med 13 (2016), 129–141.
147. Maojo, V., Kulikowski, C.A., Bioinformatics and medical informatics: collaborations on the road to genomic medicine?. J Am Med Inform Assoc 10 (2003), 515–522.
148. Carlile, S., Sefton, A.J., Healthcare and the information age: implications for medical education. Med J Aust 168 (1998), 340–343.
149. Badgeley, M.A., Shameer, K., Glicksberg, B.S., et al. EHDViz: clinical dashboard development using open-source technologies. BMJ Open, 6, 2016, e010579.
150. Vaitsis, C., Nilsson, G., Zary, N., Visual analytics in healthcare education: exploring novel ways to analyze and represent big data in undergraduate medical education. PeerJ, 2, 2014, e683.
151. Charles, C., Gafni, A., Whelan, T., Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 44 (1997), 681–692.
152. Rumsfeld, J.S., Joynt, K.E., Maddox, T.M., Big data analytics to improve cardiovascular care: promise and challenges. Nat Rev Cardiol 13 (2016), 350–359.
153. Peiris, D.P., Joshi, R., Webster, R.J., et al. An electronic clinical decision support tool to assist primary care providers in cardiovascular disease risk management: development and mixed methods evaluation. J Med Internet Res, 11, 2009, e51.
154. Chalkidou, K., Rawlins, M., Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discov Today 16 (2011), 873–877.
155. Pink, J., Pirmohamed, M., Lane, S., Hughes, D.A., Cost-effectiveness of pharmacogenetics- guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther 95 (2014), 199–207.
156. Verhoef, T.I., Redekop, W.K., Langenskiold, S., et al. Cost-effectiveness of pharmacogenetic- guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J 16 (2016), 478–484.
157. Gor, D., Kim, K., Chumnumwat, S., et al. Cost-effectiveness of a novel pharmacist guided warfarin pharmacogenetic service. Value Health, 18, 2015, A390.
158. You, J.H., Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis. Pharmacogenet Genomics 24 (2014), 6–14.
159. Li, M.J., Liu, Z., Wang, P., et al. GWASdb v2: an update database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res 44 (2016), D869–D876.